Literature DB >> 3500861

Recombinant human interleukin 5 is an eosinophil differentiation factor but has no activity in standard human B cell growth factor assays.

E Clutterbuck1, J G Shields, J Gordon, S H Smith, A Boyd, R E Callard, H D Campbell, I G Young, C J Sanderson.   

Abstract

Following the observation that mouse interleukin 5 (IL5) is active as a B cell growth factor (BCGF) as well as an eosinophil differentiation factor, this work was carried out to test recombinant human IL5 for BCGF activity. A highly active, partially purified batch of recombinant human IL5 was prepared and tested for BCGF activity in four laboratories. This batch gave a 50% endpoint of 1:77,450 in the human eosinophil differentiation assay, 1:983 in the mouse eosinophil differentiation assay and 1:42 in the mouse BCL1 assay, thus demonstrating that, like mouse IL5, human IL5 has cross-species activity. By comparison with the assays in the mouse this batch would be expected to have 50% maximal human BCGF activity of about 1:4000. In each assay a known positive factor was used as a positive control, and there was no inhibitory activity in the preparation. However, despite the activity towards the mouse B cell lymphoma, the results showed no detectable activity in a panel of assays used to identify human BCGF and B cell differentiation factors. These assays included (a) proliferation assays with tonsillar or splenic B cells in the presence of the co-stimulators anti-mu or phorbol myristate acetate; (b) a restimulation assay in which tonsillar B cells are first activated with either Staphylococcus aureus Cowan 1 or a mixture of phorbol dibutyrate and ionomycin, or splenic B cells are first activated with anti-mu; (c) production of immunoglobulin by B cells in a restimulation assay with Staphylococcus aureus Cowan 1; (d) production of immunoglobulin by the Epstein-Barr virus-transformed B lymphoblastoid CESS cell line; (e) the ability to stimulate proliferation of chronic lymphocytic leukemia (B-CLL) cells freshly explanted from three different patients; (f) the ability to stimulate the B lymphoma (L4) cell line and the mature B cell (HBF1) line, and (g) the ability to replace T cells in specific antibody responses. It therefore seems unlikely that recombinant human IL5 is either a growth or a differentiation factor for human B cells, and raises the interesting question of the biological significance of the BCGF activity of this factor in the mouse.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3500861     DOI: 10.1002/eji.1830171210

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  32 in total

1.  Eosinophils in health and disease: the LIAR hypothesis.

Authors:  J J Lee; E A Jacobsen; M P McGarry; R P Schleimer; N A Lee
Journal:  Clin Exp Allergy       Date:  2010-04       Impact factor: 5.018

2.  Effect of recombinant human tumour necrosis factor beta (TNF beta) on activation, proliferation and differentiation of human B lymphocytes.

Authors:  H Zola; A Nikoloutsopoulos
Journal:  Immunology       Date:  1989-06       Impact factor: 7.397

Review 3.  The interleukins in acquired disease.

Authors:  M Malkovský; P M Sondel; W Strober; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

Review 4.  Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.

Authors:  Peter Valent; Gerald J Gleich; Andreas Reiter; Florence Roufosse; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Karl Sotlar; Joseph H Butterfield; Sabine Cerny-Reiterer; Matthias Mayerhofer; Peter Vandenberghe; Torsten Haferlach; Bruce S Bochner; Jason Gotlib; Hans-Peter Horny; Hans-Uwe Simon; Amy D Klion
Journal:  Expert Rev Hematol       Date:  2012-04       Impact factor: 2.929

Review 5.  What targeting eosinophils has taught us about their role in diseases.

Authors:  Bruce S Bochner; Gerald J Gleich
Journal:  J Allergy Clin Immunol       Date:  2010-07       Impact factor: 10.793

6.  Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures.

Authors:  Harvey E Johnston; Matthew J Carter; Kerry L Cox; Melanie Dunscombe; Antigoni Manousopoulou; Paul A Townsend; Spiros D Garbis; Mark S Cragg
Journal:  Mol Cell Proteomics       Date:  2017-01-04       Impact factor: 5.911

7.  Heterogeneity of B cell responsiveness to interleukin 4, interleukin 6 and low molecular weight B cell growth factor in discrete stages of B cell activation in patients with systemic lupus erythematosus.

Authors:  A Kitani; M Hara; T Hirose; K Norioka; M Harigai; W Hirose; K Suzuki; M Kawakami; M Kawagoe; H Nakamura
Journal:  Clin Exp Immunol       Date:  1989-07       Impact factor: 4.330

8.  Allergy, asthma, and inflammation: which inflammatory cell type is more important?

Authors:  Redwan Moqbel; Solomon O Odemuyiwa
Journal:  Allergy Asthma Clin Immunol       Date:  2008-12-15       Impact factor: 3.406

Review 9.  Ste20-like kinase SLK, at the crossroads: a matter of life and death.

Authors:  Khalid N Al-Zahrani; Kyla D Baron; Luc A Sabourin
Journal:  Cell Adh Migr       Date:  2012-11-15       Impact factor: 3.405

10.  Flow cytometric studies of IL-4-stimulated expression of the CD25 antigen by quiescent human B lymphocyte subpopulations.

Authors:  R D Butcher; W Cushley
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.